Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study

被引：0
|
作者：
Zhang, Yong
Che, Shaomin
Chen, Nanzheng
Li, Xinju
Fu, Junke
Yu, Chenao
Wang, Tianren
Liang, Runjia
Xu, Haozhen
Wu, Qifei
Jia, Zhuoqi
Zhu, Cailin
Gong, Tuotuo
Li, Haijun
Zhang, Boxiang
Hu, Yunyun
Liu, Yaqi
机构：
[1] Xi An Jiao Tong Univ, Dept Thorac Surg, Affiliated Hosp 1, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16090
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Lv, Huilai
    Tian, Yang
    Li, Jiachen
    Huang, Chao
    Sun, Bokang
    Gai, Chunyue
    Li, Zhenhua
    Tian, Ziqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
    Kong, Yue
    Su, Miaoyi
    Fang, Jun
    Chen, Mengyuan
    Zheng, Chao
    Jiang, Youhua
    Tao, Kaiyi
    Wang, Changchun
    Qiu, Guoqin
    Ji, Yongling
    Wang, Yuezhen
    Yang, Yang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Radiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Combined with Chemotherapy
    Kong, Y.
    Ji, Y.
    Qiu, G.
    Wang, Y.
    Fang, J.
    Chen, M.
    Chen, Q.
    Jiang, Y.
    Yang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E309 - E310
  • [24] A phase II study of tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: Long-term follow-up outcomes of TD-NICE
    Jiang, T.
    Yan, X.
    Zhao, J.
    Lei, J.
    Ni, Y.
    Zhou, Y.
    Wang, X.
    Qi, H.
    Gong, L.
    Liu, H.
    Tian, F.
    Lu, Q.
    Sun, J.
    Yang, E.
    Zhong, D.
    Wang, T.
    Huang, L.
    Jiang, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S879 - S879
  • [25] Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable esophageal squamous carcinoma: an open-label, single-arm study
    Jiang, Bo
    Yang, Xin
    Zhang, Junling
    Huang, Mengli
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial
    Li, Zhigang
    Yang, Yang
    Liu, Zhichao
    Li, Chunguang
    Su, Yuchen
    Zhang, Hong
    Liu, Jun
    Zhang, Ming
    Dong, Yun
    Han, Yuchen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 443 - 443
  • [27] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] NEOADJUVANT CHEMOTHERAPY-PLUS-RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS-CELL CARCINOMA
    HELLBARDT, A
    AAPRO, M
    SAPPINO, AP
    MIRIMANOFF, RO
    MEGEVAND, R
    HELVETICA CHIRURGICA ACTA, 1989, 56 (04) : 435 - 441
  • [29] Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
    Park, Sehhoon
    Lee, Yurimi
    Lee, Jiyun
    Min, Yang Won
    Kim, Hong Kwan
    Chol, Joon Young
    Jung, Hyun Ae
    Choi, Yong Soo
    Choi, Yoon-La
    Shim, Young Mog
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 567 - 579
  • [30] A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma
    Wu, L.
    Li, J.
    Kong, Y.
    Chen, B.
    Zhou, Y.
    Pu, X.
    Luo, Y.
    Xu, L.
    Wang, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S69 - S69
12345